These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 23535927)

  • 1. Deal watch: Chiasma and Roche partner in oral peptide drug delivery.
    Harrison C
    Nat Rev Drug Discov; 2013 Apr; 12(4):255. PubMed ID: 23535927
    [No Abstract]   [Full Text] [Related]  

  • 2. Deal watch: Roche deal targets glutamate in neurodevelopmental disorders.
    Harrison C
    Nat Rev Drug Discov; 2012 Aug; 11(8):590. PubMed ID: 22814417
    [No Abstract]   [Full Text] [Related]  

  • 3. Evidence for octreotide subcutaneously in the treatment of acromegaly.
    Liuzzi A; Oppizzi G
    J Endocrinol; 1997 Oct; 155 Suppl 1():S61-5. PubMed ID: 9389999
    [No Abstract]   [Full Text] [Related]  

  • 4. [The treatment of acromegaly with octreotide].
    Rau H; Althoff PH
    Dtsch Med Wochenschr; 1993 Apr; 118(16):606-7. PubMed ID: 8482237
    [No Abstract]   [Full Text] [Related]  

  • 5. [Treatment of therapy-resistant acromegaly using Sandostatin].
    von Werder K; Mehltretter G; Müller OA
    Z Gastroenterol; 1990 Sep; 28 Suppl 2():29-31. PubMed ID: 1980775
    [No Abstract]   [Full Text] [Related]  

  • 6. Debut of a somatostatin analog: octreotide in review.
    Zindel LR
    Conn Med; 1989 Dec; 53(12):741-4. PubMed ID: 2558839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deal watch: Synta and Roche collaborate on anti-inflammatory ion channel modulators.
    Nat Rev Drug Discov; 2009 Mar; 8(3):184-5. PubMed ID: 19247298
    [No Abstract]   [Full Text] [Related]  

  • 8. Drug carriers for oral delivery of peptides and proteins: accomplishments and future perspectives.
    Reis CP; Silva C; Martinho N; Rosado C
    Ther Deliv; 2013 Feb; 4(2):251-65. PubMed ID: 23343163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Current alternative in the pharmacotherapy of acromegaly: the long-acting somatostatin analogue octreotide].
    Laczi F; Magony S; Julesz J
    Orv Hetil; 2002 May; 143(19 Suppl):1062-6. PubMed ID: 12063861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deal watch: Abbott and Neurocrine to develop promising endometriosis drug.
    Nat Rev Drug Discov; 2010 Aug; 9(8):584. PubMed ID: 20671753
    [No Abstract]   [Full Text] [Related]  

  • 11. Short-term continuous infusion of octreotide in acromegaly. Pharmacokinetics and prediction of the response to long-term treatment.
    Timsit J; Chanson P; Harris AG; Grass P; Guillausseau PJ; Warnet A; Lubetzki J
    Horm Metab Res; 1991 Jan; 23(1):48-9. PubMed ID: 2016081
    [No Abstract]   [Full Text] [Related]  

  • 12. Long-term treatment of acromegaly with a long-acting analogue of somatostatin, octreotide.
    Page MD; Millward ME; Taylor A; Preece M; Hourihan M; Hall R; Scanlon MF
    Q J Med; 1990 Feb; 74(274):189-201. PubMed ID: 2111918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deal watch: Infinity and Intellikine to develop oral PI3K inhibitors for inflammatory diseases.
    Nat Rev Drug Discov; 2010 Sep; 9(9):670. PubMed ID: 20811369
    [No Abstract]   [Full Text] [Related]  

  • 14. Effective treatment of recurrent acromegaly with a long-active somatostatin analogue (sandostatin).
    Miranda R; Zárate A; Ruíz Velasco G
    Arch Invest Med (Mex); 1988; 19(4):445-8. PubMed ID: 3245759
    [No Abstract]   [Full Text] [Related]  

  • 15. Deal watch: Alcon licenses complement pathway inhibitor for macular degeneration.
    Nat Rev Drug Discov; 2009 Dec; 8(12):922. PubMed ID: 19949394
    [No Abstract]   [Full Text] [Related]  

  • 16. Critical appraisal of a randomized trial: surgery is superior to octreotide LAR in newly diagnosed patients with acromegaly.
    Scheffel RS; Dora JM
    Clin Endocrinol (Oxf); 2010 Jul; 73(1):134; author reply 135-6. PubMed ID: 20039884
    [No Abstract]   [Full Text] [Related]  

  • 17. [Behavior of the pituitary-thyroid axis in acromegalic subjects during prolonged intermittent and pulsatile treatment with octreotide].
    Cuttica CM; Fazzuoli L; Cariola G; Carraro A; Porcella E; Giusti M; Giordano G
    Recenti Prog Med; 1994 Jan; 85(1):7-12. PubMed ID: 8184183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting therapeutic response and degree of pituitary tumour shrinkage during treatment of acromegaly with octreotide LAR.
    Jenkins PJ; Emery M; Howling SJ; Evanson J; Besser GM; Monson JP
    Horm Res; 2004; 62(5):227-32. PubMed ID: 15477693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Experience in treating acromegalic patients with long-acting octreotide].
    Szücs N; Mészáros J; Czirják S; Mondok A; Varga I; Gláz E
    Orv Hetil; 2002 May; 143(19 Suppl):1066-70. PubMed ID: 12063862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral biodrug delivery using cell-penetrating peptide.
    Khafagy el-S; Morishita M
    Adv Drug Deliv Rev; 2012 May; 64(6):531-9. PubMed ID: 22245080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.